Literature DB >> 17585054

The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity.

Maria Thereza P Barbosa1, Sandra M Soares, Colleen M Novak, David Sinclair, James A Levine, Pinar Aksoy, Eduardo Nunes Chini.   

Abstract

Obesity is one of the major health problems of our times. Elucidating the signaling mechanisms by which high-fat caloric diet induces obesity is critical for the understanding of this condition and for the development of therapeutic strategies for its treatment. Here, we demonstrate a novel role for protein CD38 as a regulator of body weight during a high-fat diet. CD38 is a ubiquitous enzyme that catalyzes the synthesis of second messengers and has been implicated in the regulation of a wide variety of signaling pathways. We report that CD38-deficient mice are protected against high-fat diet-induced obesity owing to enhanced energy expenditure. In fact, calorimetric studies indicate that CD38-deficient animals have a higher metabolic rate compared to control mice. Analysis of the mechanism revealed that this resistance to diet-induced obesity is mediated at least in part via a NAD-dependent activation of SIRT-PGC1alpha axis, a well-established cascade, involved in the regulation of mitochondrial biogenesis and energy homeostasis. Thus, together these results identify a novel pathway regulating body weight and clearly show that CD38 is a nearly obligatory component of the cellular cascade that led to diet-induced obesity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17585054     DOI: 10.1096/fj.07-8290com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  108 in total

Review 1.  Location, Location, Location: Compartmentalization of NAD+ Synthesis and Functions in Mammalian Cells.

Authors:  Xiaolu A Cambronne; W Lee Kraus
Journal:  Trends Biochem Sci       Date:  2020-06-25       Impact factor: 13.807

Review 2.  Protein acetylation in metabolism - metabolites and cofactors.

Authors:  Keir J Menzies; Hongbo Zhang; Elena Katsyuba; Johan Auwerx
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

3.  Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Authors:  Claudia C S Chini; Anatilde M Gonzalez Guerrico; Veronica Nin; Juliana Camacho-Pereira; Carlos Escande; Maria Thereza Barbosa; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2013-09-11       Impact factor: 12.531

Review 4.  The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing.

Authors:  S Imai; J Yoshino
Journal:  Diabetes Obes Metab       Date:  2013-09       Impact factor: 6.577

5.  Accurate measurement of nicotinamide adenine dinucleotide (NAD⁺) with high-performance liquid chromatography.

Authors:  Jun Yoshino; Shin-Ichiro Imai
Journal:  Methods Mol Biol       Date:  2013

Review 6.  The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

Authors:  Riekelt H Houtkooper; Carles Cantó; Ronald J Wanders; Johan Auwerx
Journal:  Endocr Rev       Date:  2009-12-09       Impact factor: 19.871

Review 7.  SIRT1 and energy metabolism.

Authors:  Xiaoling Li
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-01       Impact factor: 3.848

Review 8.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

Review 9.  CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions.

Authors:  Eduardo Nunes Chini
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

10.  Metabolic consequences of pregnancy-associated plasma protein-A deficiency in mice: exploring possible relationship to the longevity phenotype.

Authors:  Cheryl A Conover; Megan A Mason; James A Levine; Colleen M Novak
Journal:  J Endocrinol       Date:  2008-06-19       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.